- Home
- GRAF vs ITOS Comparison
GRAF vs ITOS Comparison
Compare GRAF & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAF
- ITOS
- Stock Information
- Founded
- GRAF 2021
- ITOS 2011
- Country
- GRAF United States
- ITOS United States
- Employees
- GRAF N/A
- ITOS N/A
- Industry
- GRAF
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRAF
- ITOS Health Care
- Exchange
- GRAF NYSE
- ITOS Nasdaq
- Market Cap
- GRAF 292.7M
- ITOS 270.7M
- IPO Year
- GRAF 2024
- ITOS 2020
- Fundamental
- Price
- GRAF $10.22
- ITOS $6.88
- Analyst Decision
- GRAF
- ITOS Strong Buy
- Analyst Count
- GRAF 0
- ITOS 3
- Target Price
- GRAF N/A
- ITOS $26.00
- AVG Volume (30 Days)
- GRAF 3.9K
- ITOS 384.6K
- Earning Date
- GRAF 01-01-0001
- ITOS 03-05-2025
- Dividend Yield
- GRAF N/A
- ITOS N/A
- EPS Growth
- GRAF N/A
- ITOS N/A
- EPS
- GRAF 0.30
- ITOS N/A
- Revenue
- GRAF N/A
- ITOS $35,000,000.00
- Revenue This Year
- GRAF N/A
- ITOS N/A
- Revenue Next Year
- GRAF N/A
- ITOS $121.70
- P/E Ratio
- GRAF $33.39
- ITOS N/A
- Revenue Growth
- GRAF N/A
- ITOS 177.89
- 52 Week Low
- GRAF $9.03
- ITOS $6.67
- 52 Week High
- GRAF $11.02
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- GRAF N/A
- ITOS 42.01
- Support Level
- GRAF N/A
- ITOS $6.73
- Resistance Level
- GRAF N/A
- ITOS $7.65
- Average True Range (ATR)
- GRAF 0.00
- ITOS 0.36
- MACD
- GRAF 0.00
- ITOS -0.01
- Stochastic Oscillator
- GRAF 0.00
- ITOS 21.43
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.